ES2375913T3 - Nueva clase de espiropiperidinas para el tratamiento de enfermedades neurodegenerativas. - Google Patents

Nueva clase de espiropiperidinas para el tratamiento de enfermedades neurodegenerativas. Download PDF

Info

Publication number
ES2375913T3
ES2375913T3 ES09742523T ES09742523T ES2375913T3 ES 2375913 T3 ES2375913 T3 ES 2375913T3 ES 09742523 T ES09742523 T ES 09742523T ES 09742523 T ES09742523 T ES 09742523T ES 2375913 T3 ES2375913 T3 ES 2375913T3
Authority
ES
Spain
Prior art keywords
methyl
alkyl
fluorophenyl
aunt
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09742523T
Other languages
English (en)
Spanish (es)
Inventor
Michael Aaron Brodney
Christopher John Helal
Brian Thomas O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2375913T3 publication Critical patent/ES2375913T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09742523T 2008-05-05 2009-05-04 Nueva clase de espiropiperidinas para el tratamiento de enfermedades neurodegenerativas. Active ES2375913T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5042308P 2008-05-05 2008-05-05
US50423P 2008-05-05
PCT/IB2009/051815 WO2009136350A1 (en) 2008-05-05 2009-05-04 Novel class of spiro piperidines for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ES2375913T3 true ES2375913T3 (es) 2012-03-07

Family

ID=40902870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09742523T Active ES2375913T3 (es) 2008-05-05 2009-05-04 Nueva clase de espiropiperidinas para el tratamiento de enfermedades neurodegenerativas.

Country Status (22)

Country Link
US (1) US20110046160A1 (enExample)
EP (1) EP2300484B1 (enExample)
JP (1) JP2011519913A (enExample)
KR (1) KR20110000749A (enExample)
CN (1) CN102083841A (enExample)
AP (1) AP2010005456A0 (enExample)
AT (1) ATE537178T1 (enExample)
AU (1) AU2009245322B2 (enExample)
BR (1) BRPI0912433A2 (enExample)
CA (1) CA2721786A1 (enExample)
CO (1) CO6321280A2 (enExample)
CR (1) CR11759A (enExample)
DO (1) DOP2010000317A (enExample)
EA (1) EA201001566A1 (enExample)
EC (1) ECSP10010597A (enExample)
ES (1) ES2375913T3 (enExample)
IL (1) IL208793A0 (enExample)
MA (1) MA32290B1 (enExample)
MX (1) MX2010012066A (enExample)
NZ (1) NZ588589A (enExample)
SV (1) SV2010003725A (enExample)
WO (1) WO2009136350A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2556076A2 (en) * 2010-04-09 2013-02-13 Pfizer Inc. Novel sultam compounds
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233077B1 (en) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamine d2 receptor ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2359707T3 (es) * 2004-01-08 2011-05-26 F. Hoffmann-La Roche Ag Derivados de diaza-espiropiperidina.
JP2006044497A (ja) * 2004-08-05 2006-02-16 Toyota Motor Corp 車輪情報処理装置
WO2006044497A2 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
CA2615656A1 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008030412A2 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2117309B1 (en) * 2007-01-04 2013-11-06 Merck Sharp & Dohme Corp. Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
CO6321280A2 (es) 2011-09-20
ECSP10010597A (es) 2010-12-30
CA2721786A1 (en) 2009-11-12
IL208793A0 (en) 2010-12-30
MX2010012066A (es) 2010-12-06
CR11759A (es) 2010-11-22
AU2009245322B2 (en) 2011-07-14
AP2010005456A0 (en) 2010-12-31
CN102083841A (zh) 2011-06-01
NZ588589A (en) 2012-07-27
MA32290B1 (fr) 2011-05-02
AU2009245322A1 (en) 2009-11-12
KR20110000749A (ko) 2011-01-05
DOP2010000317A (es) 2010-11-15
BRPI0912433A2 (pt) 2015-12-22
EA201001566A1 (ru) 2011-04-29
WO2009136350A1 (en) 2009-11-12
US20110046160A1 (en) 2011-02-24
EP2300484B1 (en) 2011-12-14
JP2011519913A (ja) 2011-07-14
EP2300484A1 (en) 2011-03-30
SV2010003725A (es) 2011-07-05
ATE537178T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
JP7623301B2 (ja) Ｉｌ－１７調節剤としてのイミダゾピリジン誘導体
JP4932065B2 (ja) βセクレターゼ阻害剤としてのラクタム
US20120053165A1 (en) Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators
AU2010311035B2 (en) Imidazole derivatives as casein kinase inhibitors
DK2646443T3 (en) CAT-II inhibitors
US20080312271A1 (en) Azabenzimidazolyl compounds
CA3110767A1 (en) Benzimidazolone derivatives, and analogues thereof, as il-17 modulators
EP2300484B1 (en) Novel class of spiro piperidines for the treatment of neurodegenerative diseases
JP2023551110A (ja) Ｉｌ‐１７モジュレーターとしてのジシクロプロピルメチル誘導体
US20130150376A1 (en) Novel Sultam Compounds
US20120295923A1 (en) Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators
HK1153457A (zh) 用於治疗神经变性疾病的新型螺哌啶类化合物
CA3237171A1 (en) Dioxazines and their use in treatment of gba-related diseases
WO2010087761A1 (en) 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
JP2012516326A (ja) ２−アザ−ビシクロ［２．２．１］ヘプタン化合物及びそれらの使用